Clinical Trials Logo

Rectal Neoplasms clinical trials

View clinical trials related to Rectal Neoplasms.

Filter by:

NCT ID: NCT04672603 Recruiting - Rectal Cancer Clinical Trials

Complete Versus Partial Preservation of Denonvilliers' Fascia on Urogenital Function in Locally Advanced Rectal Cancer

Start date: April 8, 2021
Phase: N/A
Study type: Interventional

Total mesorectal resection (TME) is the standard surgical method for locally advanced rectal cancer, which significantly reduces the local recurrence rate. However, the incidence of urogenital dysfunction is higher. Studies found that Denonvilliers' Fascia contains autonomic nerves that may regulate urogenital function, while traditional TME surgery resects part of it. Recent Studies found that complete preservation of Denonvilliers' Fascia could improve urogenital in selected patients with rectal cancer. Locally advanced patient (T3-4 and/or N+, M0) accounts for a high proportion of mid-low rectal cancer. However, whether these patients can benefit from it has not fully been demonstrated. This project conducts a multi-center randomized controlled study to evaluate the effects of complete preservation and partial preservation of Denonvilliers' Fascia on postoperative urogenital function of locally advanced non-anterior mid-low rectal cancer.

NCT ID: NCT04664504 Recruiting - Rectal Cancer Clinical Trials

A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk

Start date: December 1, 2020
Phase: Phase 2
Study type: Interventional

A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk

NCT ID: NCT04659148 Recruiting - Ulcerative Colitis Clinical Trials

Surgical and Oncological Outcomes in Patients With Ulcerative Colitis-associated Rectal Cancer

UC-RectalK
Start date: October 1, 2020
Phase:
Study type: Observational

This is a retrospective observational study to investigate the short-term surgical outcomes, and long-term oncological outcomes of patients diagnosed with Ulcerative colitis and rectal cancer.

NCT ID: NCT04643366 Recruiting - Rectal Cancer Clinical Trials

Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

Start date: January 28, 2021
Phase: Phase 2
Study type: Interventional

This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.

NCT ID: NCT04643041 Recruiting - Rectal Cancer Clinical Trials

Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer

BASKET
Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Immunotherapy has achieved significant therapeutic effect in DNA mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC) , more than fifty percent of dMMR/MSI-H CRC patients might get pathological complete response(pCR) after PD-1 monoclonal antibody treatment. For distant rectal cancer(RC), radical resection and neoadjuvant chemotherapy or chemoradiotherapy might cause lots of treatment cost,damage to defecation and sexual function, acute toxicity, chronic dysfunction, even loss of anus and psychological disorder. This study aims to evaluate the effect and safety of watch and wait in patients with dMMR/MSI-H distal RC accessed pCR after PD-1 monoclonal antibody therapy.

NCT ID: NCT04642924 Recruiting - Rectal Cancer Clinical Trials

SGM-101 in Locally Advanced and Recurrent Rectal Cancer

SGM-LARRC
Start date: October 22, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Near-infrared fluorescence-guided oncologic surgery (EGOS) with the use of a tumor specific tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about tumor location and extensiveness, which can be difficult to detect with conventional visual and tactile feedback. Hence, this information could aid in intra-operative decision making and therewith foster complete resection margins and less extensive surgery. Subsequently, this may drastically improve patient care by improving oncologic outcome.

NCT ID: NCT04636008 Recruiting - Rectal Cancer Clinical Trials

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Start date: August 14, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This prospective, single-arm study is conducted to investigate the safety and efficacy of Sintilimab combined with hypofractionated radiotherapy in patients with microsatellite instability-high (MSI-H)/ DNA mismatch repair-deficient (dMMR) non-metastatic rectal cancer.

NCT ID: NCT04635488 Recruiting - Rectal Cancer Clinical Trials

Prediction Model for Lateral Lymph Node Metastasis

Start date: January 1, 2020
Phase:
Study type: Observational

Mid to low-lying rectal cancer patient with enlarged lateral lymph node befor treatment and receiving lateral lymph node dissection would be enrolled. Radiomics parameters of lateral lymph nodes would be extracted by expert software. Then a part of the nodes would be used as the training set to build the prediction model, and the another part nodes would be used as the validation set.

NCT ID: NCT04622176 Recruiting - Rectal Cancer Clinical Trials

Magnetomotoric Ultrasound for Diagnostic Purposes in Rectal Cancer

MMURC
Start date: June 17, 2021
Phase:
Study type: Observational

A magnetomotive ultrasound combines standard diagnostic ultrasound equipment with the application of an external time-varying magnetic field. The investigators aim to use this equipment to improve preoperative diagnostics in rectal cancer.

NCT ID: NCT04612569 Recruiting - Rectal Cancer Clinical Trials

Feasibility and Impact of a Prehabilitation and Rehabilitation Program for the Continuity of Care in Severe Low Anterior Resection Syndrome.

PRELARS
Start date: October 1, 2020
Phase:
Study type: Observational

Patients with sphincter saving procedures of rectal cancer usually experience intestinal dysfunction, including difficulty emptying the bowel and faecal incontinence, leading to a detriment in the quality of life. A prospective study is proposed to measure de feasibility and the impact of a continuous care programme for the prevention or reduction of intestinal dysfunction disorders. The intervention lies on prehabilitation and rehabilitation with physiotherapy, biofeedback and neuromodulation, is assisted by a telematic information system (APP for the monitoring of education on physiotherapy and surveillance).